CRISPR

CRISPR3-spast

ID

ZDB-CRISPR-201110-5

Name

CRISPR3-spast

Previous Names

None

Target

spast (1)

Sequence

5' - TGTAGGTGATAAGCAGAAGGCGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ula1	spast

Expression

Gene expression in Wild Types + CRISPR3-spast

No data available

Phenotype

Phenotype resulting from CRISPR3-spast

No data available

Phenotype of all Fish created by or utilizing CRISPR3-spast

Phenotype	Fish	Conditions	Figures
skeletal muscle atl1 expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
skeletal muscle bscl2 expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
skeletal muscle N-docosanoylsphingosine decreased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
fast muscle cell endoplasmic reticulum aggregated, abnormal	spast^ula1/ula1	standard conditions	Fig 3 from Arribat et al., 2020
skeletal muscle spartb expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
skeletal muscle reep1 expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
whole organism decreased length, abnormal	spast^ula1/ula1	standard conditions	Fig 2 from Arribat et al., 2020
brain atl1 expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
yolk anatomical region increased accumulation fat cell, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
whole organism lipid droplet decreased size, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
skeletal muscle cholesteryl ester decreased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
aerobic respiration decreased magnitude, abnormal	spast^ula1/ula1	standard conditions	Fig 2 from Arribat et al., 2020
head lipid increased amount, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
blood vessel lipid increased amount, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
swim bladder anatomical region increased accumulation fat cell, abnormal	spast^ula1/ula1	standard conditions	Fig 3 from Arribat et al., 2020
skeletal muscle hexadecatrienoic acid decreased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
swimming decreased occurrence, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
slow muscle cell endoplasmic reticulum flattened, abnormal	spast^ula1/ula1	standard conditions	Fig 3 from Arribat et al., 2020
hatching delayed, abnormal	spast^ula1/ula1	standard conditions	Fig 2 from Arribat et al., 2020
brain phosphatidylethanolamine 34:0 zwitterion increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
whole organism lipid droplet condensed, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
swimming decreased occurrence, abnormal	spast^ula1/ula1	chemical treatment by environment: tunicamycin	Fig 3 from Arribat et al., 2020
brain phosphatidylethanolamine 40:3 zwitterion increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
brain N-octadecanoylsphingosine decreased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
swimming decreased linear velocity, abnormal	spast^ula1/ula1	chemical treatment by environment: tunicamycin	Fig 3 from Arribat et al., 2020
whole organism lipid droplet increased distribution, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
whole organism lipid droplet increased amount, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
skeletal muscle hexadecanoic acid decreased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
swimming decreased linear velocity, abnormal	spast^ula1/ula1	chemical treatment by environment: oleic acid	Fig 3 from Arribat et al., 2020
brain reep1 expression increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 7 from Arribat et al., 2020
brain phosphatidylethanolamine 36:1 zwitterion increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020
whole organism decreased weight, abnormal	spast^ula1/ula1	standard conditions	Fig 2 from Arribat et al., 2020
brain phosphatidylethanolamine 36:2 zwitterion increased amount, abnormal	spast^ula1/ula1	standard conditions	Fig 8 from Arribat et al., 2020

Citations